Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis
JNCI: Journal of the National Cancer Institute · 2024
DOI: 10.1093/jnci/djae137 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Xianjing Chu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 114 Literaturangaben. Gefördert von: Clinical Research Special Fund of Wu Jieping Medical Foundation, Xiangya Hospital, Central South University, Chen Xiao-Ping Foundation.
Abstract (Originalsprache)
Introduction
Programmed death 1 (PD-1)/programmed death 1 ligand 1 (PD-L1)-directed immunotherapy has revolutionized the treatments for advanced non-small cell lung cancer (NSCLC), whereas the optimal therapeutic combinations remain uncertain.
Methods
Our study encompassed phase II/III randomized controlled trials (RCTs) that involved anti-PD-(L)1-based therapies for stage-IV NSCLC. The primary outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and incidences of adverse events. Subgroup analyses were conducted by treatment lines, PD-L1 expression levels, histological types, and metastatic sites.
Results
Our analysis incorporated 38 publications, covering 14 therapeutic combinations and involving 18 048 participants. PD-(L)1+chemotherapy (CT), PD-(L)1+ cytotoxic T lymphocyte-associated antigen-4 (CTLA4) +CT, and PD-(L)1+ T-cell immunoglobulin and ITIM domain were notably effective in prolonging OS. Overall, PD-(L)1+CT and PD-(L)1+CT+ vascular endothelial growth factor (VEGF) were significantly beneficial for PFS and ORR. As for the subsequent-line treatments, incorporating radiotherapy can enhance PFS and ORR (ranked fourth among enrolled treatments). For patients with PD-L1 <1%, PD-(L)1+CT+VEGF and PD-(L)1+CTLA4+CT were favorable approaches. Conversely, in patients with PD-L1 ≥50%, PD-(L)1+CT represented an effective treatment. Patients with nonsquamous cell carcinoma or liver metastases might benefit from the addition of VEGF. In cases of squamous cell carcinoma or brain metastases, the combination of PD-(L)1+CTLA4+CT yielded superior benefits.
Conclusions
This study underscores the enhanced efficacy of combination immunotherapies over monotherapy. It highlights the necessity for personalized treatment, considering individual factors. These insights are vital for clinical decision making in the management of advanced NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
- Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
ORCID-Profile: Rongrong Zhou
Förderung
- Clinical Research Special Fund of Wu Jieping Medical Foundation
- Xiangya Hospital, Central South University
- Chen Xiao-Ping Foundation
- Development of Science and Technology of Hubei Province
- Advanced Lung Cancer Targeted Therapy Research Foundation of China
- National Multidisciplinary Cooperative Diagnosis and Treatment Capacity
Zitieren
APA
Chu, X., Tian, W., Ning, J., & Zhou, R. (2024). Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae137
Vancouver
Chu X, Tian W, Ning J, Zhou R. Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae137
BibTeX
@article{Chu2024,
author = {Chu, Xianjing and Tian, Wentao and Ning, Jiaoyang and Zhou, Rongrong},
title = {Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network meta-analysis},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2024},
doi = {10.1093/jnci/djae137}
}
EUVIMED